2-(4-chlorophenyl)-2,5-dihydro-5-methyl-3H-pyrazolo<3,4-d>thieno<3,2-b>pyridin-3-one | 96516-13-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-chlorophenyl)-2,5-dihydro-5-methyl-3H-pyrazolo<3,4-d>thieno<3,2-b>pyridin-3-one
• 英文别名: 4-(4-Chlorophenyl)-8-methyl-12-thia-3,4,8-triazatricyclo[7.3.0.02,6]dodeca-1(9),2,6,10-tetraen-5-one
• CAS: 96516-13-1
• 化学式: C₁₅H₁₀ClN₃OS
• 分子量: 315.783
• InChiKey: DMDACCITSSWAMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  64.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  Methyl 7-chlorothieno[3,2-B]pyridine-6-carboxylate 在 sodium hydride 作用下， 以 xylene 为溶剂， 反应 26.5h， 生成 2-(4-chlorophenyl)-2,5-dihydro-5-methyl-3H-pyrazolo<3,4-d>thieno<3,2-b>pyridin-3-one
  参考文献：
  名称：

  Synthesis and evaluation of a series of aryl[e]fused pyrazolo[4,3-c]pyridines with potential anxiolytic activity

  摘要：

  A series of pyrazolo[4,3-c]pyridines has been synthesized and evaluated as potential anxiolytic agents. Selected compounds from this series show a pharmacological profile of action different from that of diazepam. A number of the compounds possess higher affinity for central benzodiazepine receptors than diazepam, yet show less anticonvulsant activity and are less sedative. The structure-activity relationships of these potential anxiolytic agents are discussed.

  DOI：

  10.1021/jm00171a046

文献信息

• Anxiolytic and anti-depressant thienopyridine derivatives
  申请人：BEECHAM GROUP PLC

  公开号：EP0126970A2

  公开（公告）日：1984-12-05

  Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein: G together with the two carbon atoms to which it is bonded is a thieno moiety; R, is phenyl optionally substituted by one or more C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, hydroxy, C2-7 alkanoyl, halo, trifuluoromethyl, nitro, amino optionally substituted by one or two C1-6 alkyl groups or by C2- 7 alkanoyl, cyano, carbamoyl or carboxy groups; or pyridyl optionally substituted by C1-6 alkyl or halo; R6 is hydrogen, c1-6 alkyl or phenyl optionally substituted as defined hereinbefore for R1 when phenyl; R8 is hydrogen, one of the optional substituents recited hereinbefore for R, when phenyl or phenyl optionally substituted as defined hereinbefore for R, when phenyl; and either R2 is hydrogen, or C1-6 alkyl optionally substituted by hydroxy, amino disubstituted by C1-6 alkyl, or phenyl optionally substituted as defined hereinbefore for R, when phenyl; R3 and R4 together represent a bond; R5 and R7 together represent a bond; and R9 is hydrogen and R10 is hydroxy, C1-6 alkoxy or amino optionally substituted by one or two independently selected C1-6 alkyl groups or by phenyl optionally substituted as defined hereinbefore for R, when phenyl, or Rg and R,o together represent a bond; or R2 and R3 together represent a bond; R4 and R5 together represent a bond; and R7 is hydrogen, C1-6 alkyl optionally substituted by hydroxy, amino disubstituted by c1-6 alkyl, or phenyl optionally substituted as defined hereinbefore for R, when phenyl; and R9 and R10 together represent a bond, having pharmacological activity, a process and intermediates for their preparation, compositions containing them and their use in the treatment of mammals.

  式(I)化合物及其药学上可接受的盐类： 其中 G 与其结合的两个碳原子是噻吩基； R，是任选被一个或多个 C1-6 烷基、C1-6 烷氧基、C1-6 烷硫基、羟基、C2-7 烷酰基、卤代、三氟甲基、硝基、任选被一个或两个 C1-6 烷基或 C2- 7 烷酰基、氰基、氨基甲酰基或羧基取代的苯基；或任选被 C1-6 烷基或卤代取代的吡啶基； R6 是氢、C1-6 烷基或前面定义的任选被 R1 取代的苯基（当为苯基时）； R8 是氢、前文所述 R 的任选取代基之一（当为苯基时）或任选被前文定义的 R 的任选取代基取代的苯基（当为苯基时）；以及 R2 是氢，或任选被羟基、被 C1-6 烷基取代的氨基或任选被前文定义的 R 的任选取代基取代的苯基取代的 C1-6 烷基（当为苯基时）； R3 和 R4 共同代表一个键； R5 和 R7 共同代表一个键；以及 R9 是氢，R10 是羟基、C1-6 烷氧基或氨基，可任选被一个或两个独立选择的 C1-6 烷基取代，或被前文定义的苯基任选取代的 R（当为苯基时），或 Rg 和 R,o 共同代表键； 或 R2 和 R3 共同代表一个键； R4 和 R5 共同代表一个键；以及 R7 是氢、任选被羟基取代的 C1-6 烷基、被 c1-6 烷基取代的氨基或任选被前文定义的 R 取代的苯基（当为苯基时）； 和 R9 和 R10 共同代表一种具有药理活性的键、制备它们的工艺和中间体、含有它们的组合物以及它们在治疗哺乳动物中的用途。
• FORBES, IAN T.;JOHNSON, CHRISTOPHER N.;JONES, GRAHAM E.;LOUDON, JULIA;NIC+, J. MED. CHEM., 33,(1990) N, C. 2640-2645
  作者：FORBES, IAN T.、JOHNSON, CHRISTOPHER N.、JONES, GRAHAM E.、LOUDON, JULIA、NIC+

  DOI：——

  日期：——